In search of druggable targets for GBM amino acid metabolism
Open Access
- 28 February 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-12
Abstract
Amino acid (AA) pathways may contain druggable targets for glioblastoma (GBM). Literature reviews and GBM database ( http://r2.amc.nl ) analyses were carried out to screen for such targets among 95 AA related enzymes. First, we identified the genes that were differentially expressed in GBMs (3 datasets) compared to non-GBM brain tissues (5 datasets), or were associated with survival differences. Further, protein expression for these enzymes was also analyzed in high grade gliomas (HGGs) (proteinatlas.org). Finally, AA enzyme and gene expression were compared among the 4 TCGA (The Cancer Genome Atlas) subtypes of GBMs. We detected differences in enzymes involved in glutamate and urea cycle metabolism in GBM. For example, expression levels of BCAT1 (branched chain amino acid transferase 1) and ASL (argininosuccinate lyase) were high, but ASS1 (argininosuccinate synthase 1) was low in GBM. Proneural and neural TCGA subtypes had low expression of all three. High expression of all three correlated with worse outcome. ASL and ASS1 protein levels were mostly undetected in high grade gliomas, whereas BCAT1 was high. GSS (glutathione synthetase) was not differentially expressed, but higher levels were linked to poor progression free survival. ASPA (aspartoacylase) and GOT1 (glutamic-oxaloacetic transaminase 1) had lower expression in GBM (associated with poor outcomes). All three GABA related genes -- glutamate decarboxylase 1 (GAD1) and 2 (GAD2) and 4-aminobutyrate aminotransferase (ABAT) -- were lower in mesenchymal tumors, which in contrast showed higher IDO1 (indoleamine 2, 3-dioxygenase 1) and TDO2 (tryptophan 2, 3-diaxygenase). Expression of PRODH (proline dehydrogenase), a putative tumor suppressor, was lower in GBM. Higher levels predicted poor survival. Several AA-metabolizing enzymes that are higher in GBM, are also linked to poor outcome (such as BCAT1), which makes them potential targets for therapeutic inhibition. Moreover, existing drugs that deplete asparagine and arginine may be effective against brain tumors, and should be studied in conjunction with chemotherapy. Last, AA metabolism is heterogeneous in TCGA subtypes of GBM (as well as medulloblastomas and other pediatric tumors), which may translate to variable responses to AA targeted therapies.Keywords
This publication has 37 references indexed in Scilit:
- Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II InhibitorInternational Journal of Environmental Research and Public Health, 2012
- Targeting cancer metabolism: a therapeutic window opensNature Reviews Drug Discovery, 2011
- Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell ImmunotherapyClinical Cancer Research, 2011
- Signal transduction inhibitors and antiangiogenic therapies for malignant gliomaGlia, 2011
- Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular CarcinomaJournal of Clinical Oncology, 2010
- Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitorsNeuro-Oncology, 2010
- Cancer research: from folate antagonism to molecular targetsBest Practice & Research Clinical Haematology, 2009
- Pregabalin and gabapentin inhibit substance P‐induced NF‐κB activation in neuroblastoma and glioma cellsJournal of Cellular Biochemistry, 2008
- Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase FormulationsClinical Pharmacokinetics, 2005
- Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic LeukemiaClinical Cancer Research, 2004